Via practica 5/2011

Modern therapy of respiratory diseases by third-generation cephalosporines

Third-generation cephalosporines came in clinical praxis in early nineties of the 20-th century. They were answer to worldwide growing up resistance for beta-lactamase antibiotics. Production of penicilinases, beta-lactamases and cefalosporinases by major respiratory pathogens (S. pyogenes, S. pneumoniae, H. influenzae and M. catarrhalis) notable discard shieldless penicilins, and cephalosporines of the 1-st and 2-nd generation. In Europe evoke these pathogens more than 70 – 80% of communal respiratory infections. Effect of thirdgeneration cephalosporines against strains of gram negative enterobacteria, which usually impress nosocomial infections is verified. Today we have in Slovakia two kinds of third-generation cephalosporines – ceftibuten (Cedax by Merck Sharp&Dohme) and cefixim (Suprax by Gedeon Richter).

Keywords: third-generation cephalosporines, ceftibuten, streptococcus angina, otitis media, bacterial sinusitis, acute bronchitis, acute exacerbation of chronical bronchitis, nosocomial infection